MATILDE疗法辅以放疗是治疗原发性CNS淋巴瘤的有效方案

MATILDE regimen followed by radiotherapy is an active strategy against primary CNS lymphomas

The authors assessed MATILDE chemotherapy followed by response-tailored radiation therapy in 41 patients aged 70 years or younger with primary CNS lymphoma in a Phase II trial. With response rates of 76%after MATILDE and 83%after chemotherapy with or without radiation therapy, this was an active strategy, particularly in low-to intermediate-risk patients (International Extranodal Lymphoma Study Group [IELSG]-score). Myelosuppression was the dose-limiting toxicity, with 9.5%of lethal complications. After a median follow-up of 49 months, a plateau in the survival curve (5-year overall survival: 41 ±7%) was obtained.

The authors assessed MATILDE chemotherapy followed by response-tailored radiation therapy in 41 patients aged 70 years or younger with primary CNS lymphoma in a Phase Ⅱ trial. With response rates of 76% after MATILDE and 83% after chemotherapy with or without radiation therapy, this was an active strategy, particularly in low-to intermediate-risk patients （International Extranodal Lymphoma Study Group [IELSG] -score） . Myelosuppression was the dose-limiting toxicity, with 9.5% of lethal complications. After a median follow-up of 49 months, a plateau in the survival curve （5-year overall survival： 41 ± 7% ） was obtained.